Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Thinking About Buying Stock In MercardoLibre, Diamondback Energy Or Hims & Hers Health?

Published 22/02/2022, 20:46
Updated 22/02/2022, 21:41
© Reuters.  Thinking About Buying Stock In MercardoLibre, Diamondback Energy Or Hims & Hers Health?

© Reuters. Thinking About Buying Stock In MercardoLibre, Diamondback Energy Or Hims & Hers Health?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

Here are the latest analyst rating updates for MercadoLibre , Inc. (NASDAQ: NASDAQ:MELI), Diamondback Energy Inc (NASDAQ: FANG) and Hims & Hers Health Inc (NYSE: HIMS):

The latest price target for MercadoLibre was by Jefferies on Jan. 7. The analyst firm set a price target of $1,250, a possible 33.37% upside. Fourteeen analyst firms have reported ratings in the last year.

Traders and investors will be watching for MercardoLibre’s fourth-quarter earnings report, confirmed for Tuesday after market close.

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 132 million active buyers and 1 million active sellers across its 18-country footprint.

The latest price target for Diamondback Energy was reported by Morgan Stanley (NYSE:MS) on Jan. 25. The analyst firm set a price target of $155, a possible 18% upside. Forty-one analyst firms have reported ratings in the last year.

Diamondback Energy’s fourth-quarter earnings report is confirmed for Tuesday’s after-hours session.

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin.

The latest price target for Hims & Hers Health was reported by Citigroup (NYSE:C) on Dec. 20. The analyst firm set a price target of $9, representing a possible 104.78% upside. Seven analyst firms have reported ratings in the last year.

Hims & Hers Health’s fourth-quarter earnings report is confirmed for Tuesday’s after-hours session.

Hims & Hers Health is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access medical care for conditions related to mental health, sexual health, dermatology, primary care and more.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.